Malignes Melanom beim alten und geriatrischen Patienten

  • Raphael Reinhard
  • Christoffer Gebhardt
  • Jochen Utikal
Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Patienten mit malignem Melanom sollten in allen Stadien, wenn keine Kontraindikationen bestehen und soweit möglich, in kurativer Intention primär operiert werden. In den letzten Jahren haben sich in der palliativen Situation des fortgeschrittenen, nicht resektablen Melanoms deutliche Fortschritte ergeben. So können seit 2011 durch den Einsatz von Immuntherapeutika und zielgerichteten Therapien das progressionsfreie Überleben und das Gesamtüberleben deutlich verbessert werden. Allerdings sind diese Therapieformen mit spezifischen Nebenwirkungen behaftet, die beim geriatrischen Patienten in Betracht gezogen werden müssen.

Literatur

  1. Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H (2013) Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 3(8):862–869CrossRefPubMedGoogle Scholar
  2. Ascierto PA, Minor D, Ribas A, Lebbe C, O’Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin AM, Mazumdar J, Goodman VL, Trefzer U (2013) Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 31(26):3205–3211CrossRefPubMedGoogle Scholar
  3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206CrossRefPubMedPubMedCentralGoogle Scholar
  4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516CrossRefPubMedPubMedCentralGoogle Scholar
  5. Daud A, Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W, Weber JS, Gangadhar TC, Joseph RW, Dronca RS, Patnaik A, Zarour HM, Kefford R, Lindia JA, Li XN, Ebbinghaus S, Kang SP, Hamid O (2015) Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 33 (suppl; abstr 9005)Google Scholar
  6. Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Salès F, Schadendorf D, Patel P, Dummer R (2012) Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48(2):218–225CrossRefPubMedGoogle Scholar
  7. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D, METRIC Study Group (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107CrossRefPubMedGoogle Scholar
  8. Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz T, Umansky L, Beckhove P, Sucker A, Schadendorf D, Utikal J, Umansky V (2015) Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res 21(24):5453–5459CrossRefPubMedGoogle Scholar
  9. Gebhardt C, Lichtenberger R, Utikal J (2016) Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. J Dtsch Dermatol Ges 14(2):158–164PubMedGoogle Scholar
  10. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723CrossRefPubMedPubMedCentralGoogle Scholar
  11. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O’Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE (2013) Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 31(26):3182–3190CrossRefPubMedPubMedCentralGoogle Scholar
  12. Hodi FS, Postow MA, Chesney JA, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen MF, Ernstoff MS, Minor DR, Salama A, Taylor MH, Ott PA, Horak CE, Gagnier P, Wolchok JD (2015) Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. J Clin Oncol 33(suppl; abstr 9004)Google Scholar
  13. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L (2012) A landscape of driver mutations in melanoma. Cell 150(2):251–263CrossRefPubMedPubMedCentralGoogle Scholar
  14. Jylling AM, Rasmussen AA, Jakobsen EH, de Pont Christensen R, Sørensen FB (2014) Are mutations in K-RAS, BRAF and PIK3CA genes critical for response to adjuvant trastuzumab treatment in patients with HER-2 positive breast cancer? J Cancer Ther Res 3(1):3CrossRefGoogle Scholar
  15. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20):1867–1876CrossRefPubMedGoogle Scholar
  16. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34CrossRefPubMedPubMedCentralGoogle Scholar
  17. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkotter C, Kaatz M, Schulte KW, Lehmann P, Vogt T (2015) Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: a multicenter, randomized DECOG trial. ASCO annual meeting proceedings 2015 Jun 20, Bd. 33, Nr. 18 Suppl, S LBA9002Google Scholar
  18. Leitlinienprogramm Onkologie (2016) (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 2.0, AWMF Registernummer: 032/024OL, http://leitlinienprogrammonkologie.de/Melanom.65.0.html. Zugegriffen am 24.08.2016
  19. Lejeune FJ, Macher E, Kleeberg U, Rumke P, Prade M, Thomas D, Suciu S (1988) An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase III adjuvant study. EORTC protocol 18761. Eur J Cancer Clin Oncol 24:81–90Google Scholar
  20. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371(20):1877–1888CrossRefPubMedGoogle Scholar
  21. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe CJouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386(9992):444–451CrossRefPubMedGoogle Scholar
  22. Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J (2013) Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol 27(1):11–18CrossRefPubMedGoogle Scholar
  23. McArthur GA, Chapman PB, Robert C et al (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323–332CrossRefPubMedPubMedCentralGoogle Scholar
  24. Orouji E, Ziegler B, Umansky V, Gebhardt C, Utikal J (2014) Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report. Medicine (Baltimore) 93(28):e161CrossRefGoogle Scholar
  25. Prens SP, van der Ploeg AP, van Akkooi AC, van Montfort CA, van Geel AN, de Wilt JH, Eggermont AM, Verhoef C (2011) Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site. Ann Surg Oncol 18(13):3586–3592CrossRefPubMedPubMedCentralGoogle Scholar
  26. Raizer JJ et al (2008) Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 10(2):199–207CrossRefPubMedPubMedCentralGoogle Scholar
  27. Robert Koch-Institut (2015) Krebs in Deutschland 2011/2012, 10. Ausgabe. Berlin http://www.gekid.de/Doc/krebs_in_deutschland_2015.pdf. Zugegriffen am 23.08.2016
  28. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, KEYNOTE-006 Investigators (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532CrossRefPubMedGoogle Scholar
  29. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from Phase II and Phase III trials of Ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889–1894CrossRefPubMedPubMedCentralGoogle Scholar
  30. Schilling B, Sondermann W, Zhao F, Griewank KG, Livingstone E, Sucker A, Zelba H, Weide B, Trefzer U, Wilhelm T, Loquai C, Berking C, Hassel J, Kähler KC, Utikal J, Al Ghazal P, Gutzmer R, Goldinger SM, Zimmer L, Paschen A, Hillen U, Schadendorf D, DeCOG (2014) Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol 25(3):747–753CrossRefPubMedPubMedCentralGoogle Scholar
  31. Stadler S, Weina K, Gebhardt C, Utikal J (2015) New therapeutic options for advanced non-resectable malignant melanoma. Adv Med Sci 60(1):83–88CrossRefPubMedGoogle Scholar
  32. Thiam A, Zhao Z, Quinn C, Barber B (2016) Years of life lost due to metastatic melanoma in 12 countries. J Med Econ 19(3):259–264CrossRefPubMedGoogle Scholar
  33. Topalian SL, Sznol M, McDermott DF et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving Nivolumab. J Clin Oncol 32(10):1020–1030CrossRefPubMedPubMedCentralGoogle Scholar
  34. Umansky V, Utikal J, Gebhardt C (2016) Predictive immune markers in advanced melanoma patients treated with ipilimumab. Oncoimmunology 5(6):e1158901CrossRefPubMedPubMedCentralGoogle Scholar
  35. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, Bufalino R, Cascinelli N, Cocconi G, Durand J, De Marsillac J (1982) A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307(15):913–916CrossRefPubMedGoogle Scholar
  36. Weir HK et al (2015) The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer.  https://doi.org/10.1002/cncr.29258Google Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Raphael Reinhard
    • 1
  • Christoffer Gebhardt
    • 1
  • Jochen Utikal
    • 2
  1. 1.Klinik für Dermatologie, Venerologie und AllergologieUniversitätsmedizin Mannheim der Universität Heidelberg und Deutsches Krebsforschungszentrum (DKFZ)MannheimDeutschland
  2. 2.Klinische Kooperationseinheit DermatoonkologieUniversitätsmedizin Mannheim der Universität Heidelberg und Deutsches Krebsforschungszentrum (DKFZ)MannheimDeutschland

Section editors and affiliations

  • Nicolai Härtel
    • 1
  1. 1.Interdisziplinäres TumorzentrumUniversitätsmedizin MannheimMannheimDeutschland

Personalised recommendations